These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17626754)

  • 1. [Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer].
    Yang L; Zhu X; Ran L
    Ai Zheng; 2007 Jul; 26(7):756-61. PubMed ID: 17626754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
    Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
    Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of the genes FHIT, Bcl-2 and Bax in breast infiltrating ductal carcinoma and clinicopathological significance thereof].
    Wang ZB; Zhao P; Liu M; Li XH
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(31):2171-6. PubMed ID: 17064501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
    Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer].
    Wang Y; Yao L; Liu YQ; Xu Y; Ou YT; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):511-4. PubMed ID: 21029694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and prognostic value of transcriptional factor sp1 in breast cancer].
    Wang XB; Peng WQ; Yi ZJ; Zhu SL; Gan QH
    Ai Zheng; 2007 Sep; 26(9):996-1000. PubMed ID: 17927860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
    Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.